Tumor xenografts play a major role in the development of new cancer therapies. However, one drawback of traditional xenografts is the lack of an immunological-competent host.
Over the past decade, there have been improvements in the development of preclinical models for the evaluation of the efficacy of checkpoint inhibition-based cancer immunotherapies. The recently developed humanized mouse models offer a unique tool to assess the anti-tumor response of the human immune system to checkpoint inhibitors.
In this webinar, we present our studies on both PDX and traditional xenograft mouse models, evaluating the response to immune checkpoint inhibitors in humanized mouse models.
- Julia Schüler, PhD, DVM, Head, in vivo Operations, Charles River
- Paula Miliani de Marval, PhD, Senior Research Scientist, Charles River